1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) Uses, Dosage, Side Effects and more
Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label]. The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.
Palmitoyloleoyl-phosphatidylglycerol is a replacement surfactant which prevents alveolar collapse when administered intratracheally.
| Trade Name | 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) |
| Generic | 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) |
| 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) Other Names | 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), Palmitoyloleoyl-phosphatidylglycerol, PG(16:0/18:1), POPG |
| Type | |
| Formula | C40H77O10P |
| Weight | Average: 749.02 Monoisotopic: 748.525435677 |
| Groups | Approved, Experimental |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) is a synthetic lung surfactant used to treat infant respiratory distress syndrome.
Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin which was indicated for the prevention of respiratory distress syndrome in premature infants.
How 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) works
Palmitoyloleoyl-phosphatidylglycerol reduces interfacial tension at the air/water interfaces in the alveoli [FDA Label]. This prevents the tension from pulling the alveolar membranes inwards which would collapse them and lead to respiratory distress.
